+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Cardiac Marker Testing Market by Product (Reagent, Instrument), Component (Troponin I & T, CK-MB, Myoglobin, BNP, hsCRP), Disease (Myocardial Infarction, Congestive Heart Failure, Atheresclerosis), End-user (Lab, PoC, Academia), and Region - Forecast to 2025

  • ID: 5238636
  • Report
  • January 2021
  • Region: Global
  • 163 Pages
  • Markets and Markets
Global Cardiac Marker Testing Market Projected to Reach US$ 5.5 Billion by 2025 from US$ 3.6 Billion in 2020, at a CAGR of 8.9%

FEATURED COMPANIES

  • Abbott Laboratories
  • bioMérieux SA
  • Danaher Corporation
  • Diasorin
  • F. Hoffmann-La Roche AG
  • LSI Medience Corporation

The global cardiac marker testing market is projected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2020, at a CAGR of 8.9%.



The growth in the cardiac marker testing market is majorly driven by the growing incidence of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public and private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers. However, factors such as technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are expected to restrain market growth to a certain extent.

The cardiac marker testing market is also faced a period of short-term negative growth, which can be attributed to factors such as a greater than 50% drop in the number of patients with cardiovascular conditions and those diagnosed with myocardial infarction. All areas of cardiology service provision sustained significant reductions, which included outpatient clinics, investigations, procedures, and cardiology community services such as cardiac rehabilitation.

Wide use of reagents and kits in all basic diagnostic activities in laboratories, academic institutes, and POC settings is expected to result in the segment occupying the majority of the cardiac marker testing market share

Growing number of cardiac marker testing procedures, accessibility to a wide range of cardiac biomarker reagents and kits, and the growing demand for reliable, specific, and faster detection of cardiovascular diseases at an early stage are the key growth factors for this segment.

Troponin I and T estimated to be the fastest-growing market

Troponin I and T is estimated to be the fastest-growing segment in the cardiac marker testing market. The large share of this segment can be attributed high sensitivity and specificity, long elevation times, and rapid prediction of outcome or mortality.

The Asia-Pacific market to grow at the highest CAGR during the forecast period

The cardiac marker testing market is segmented into five major regions, namely, North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Asia-Pacific is estimated to be the fastest-growing market for cardiac marker testing during the forecast period. The Asia-Pacific market is driven due increased healthcare spending by a larger population base, healthcare infrastructure modernization, and the rising penetration of cutting-edge clinical laboratory technologies (especially in rural areas) in Asia-Pacific countries.

Research Coverage

This report studies the cardiac marker testing market based on the product, biomarker type, disease, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

The major players operating in the cardiac marker testing market are Roche Diagnostics Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), bioMérieux SA (France), LSI Medience Corporation (Japan), Ortho Clinical Diagnostics (US), Randox laboratories Ltd. (UK), Guangzhou Wondfo Biotech Co., Ltd (China), DiaSorin S.p.A. (Italy), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), PerkinElmer Inc. (US), Thermo Fisher Scientific Inc. (US), and Tosoh Corporation (Japan).

Breakdown of supply-side primary interviews:

  • By Company Type: Tier 1: 48%, Tier 2: 36%, and Tier 3: 16%
  • By Designation: C-level: 10%, D-level: 14%, and Others: 76%
  • By Region: North America: 40%, Europe: 32%, APAC: 20%, Latin America: 5%, and the Middle East & Africa: 3%

Key Benefits of Buying the Report

This report focuses on various levels of analysis - industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the cardiac marker testing market, and high-growth regions and their drivers, restraints, opportunities, and challenges. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • bioMérieux SA
  • Danaher Corporation
  • Diasorin
  • F. Hoffmann-La Roche AG
  • LSI Medience Corporation

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Inclusions & Exclusions of the Study
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency Used for the Study
1.5 Stakeholders
1.6 Summary of Changes

2 Research Methodology
2.1 Research Data
Figure 1 Research Design
2.1.1 Secondary Data
2.1.1.1 Indicative List of Secondary Sources
2.1.2 Primary Data
Figure 2 Breakdown of Primaries: Cardiac Marker Testing Market
2.2 Market Estimation Methodology
Figure 3 Research Methodology: Hypothesis Building
2.2.1 Revenue Mapping-Based Market Estimation
2.2.2 End-user-Based Market Estimation
Figure 4 Market Size Estimation: Cardiac Marker Testing Market
2.2.3 Primary Research Validation
2.3 Data Triangulation
Figure 5 Data Triangulation Methodology
2.4 Research Assumptions
2.5 Research Limitations

3 Executive Summary
Figure 6 Cardiac Marker Testing Market, by Biomarker Type, 2020 Vs. 2025 (USD Million)
Figure 7 Cardiac Marker Testing Market, by End-user, 2020 Vs. 2025 (USD Million)
Figure 8 Geographical Snapshot of the Cardiac Marker Testing Market

4 Premium Insights
4.1 Cardiac Marker Testing Market Overview
Figure 9 Increasing Incidence of Cardiovascular Diseases to Drive Market Growth
4.2 Cardiac Marker Testing Market Share, by Product, 2020 Vs. 2025
Figure 10 Reagents & Kits Segment Will Continue to Dominate the Cardiac Marker Testing Market in 2025
4.3 Cardiac Marker Testing Market, by Region, 2020-2025
Figure 11 APAC Region to Register the Highest Growth Rate During the Forecast Period

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Figure 12 Cardiac Marker Testing Market: Drivers, Restraints, and Opportunities
5.2.1 Drivers
5.2.1.1 Growing Incidence of Cardiovascular Diseases
5.2.1.2 Rapidly Increasing Geriatric Population and the Subsequent Increase in the Burden of Heart Diseases Worldwide
5.2.1.3 Growing Funding from Public and Private Organizations for Research on Cardiac Biomarkers
5.2.1.4 Ongoing Clinical Trials for the Identification of Novel Cardiac Biomarkers
5.2.2 Restraints
5.2.2.1 Technical Problems Related to Sample Collection and Storage
5.2.2.2 Issues Related to Regulatory and Reimbursement Systems
5.2.3 Opportunities
5.2.3.1 Point-Of-Care Testing (POCT) with Cardiac Biomarkers
5.2.3.2 Ongoing Research on Novel Cardiac Biomarkers for Cardiovascular Diseases
5.2.3.3 Emerging Markets to Offer High-Growth Opportunities for Market Players
5.3 COVID-19 Impact on the Cardiac Marker Testing Market
5.4 Regulatory Analysis
5.4.1 US
Table 1 US: Classification of in Vitro Diagnostic Devices
Figure 13 US: Regulatory Process for IVD Devices
5.4.2 Canada
Figure 14 Canada: Regulatory Process for IVD Devices
5.4.3 Europe
Table 2 Europe: Classification of IVD Devices
Figure 15 Europe: Regulatory Process for IVD Devices
5.4.4 Japan
Figure 16 Japan: Regulatory Process for IVD Devices
Table 3 Japan: Classification of IVD Reagents
Table 4 Japan: Time, Cost, and Complexity of Registration Process
5.4.5 China
Table 5 China: Time, Cost, and Complexity of Registration Process
5.4.6 India
Figure 17 India: Regulatory Process for IVD Devices
5.4.7 Russia
Table 6 Russia: Classification of IVD Devices
5.4.8 Mexico
Figure 18 Mexico: Regulatory Process for IVD Devices
Table 7 Mexico: Time, Cost, and Complexity of Registration Process
5.4.9 Brazil
Figure 19 Brazil: Regulatory Process for IVD Devices
5.4.10 South Korea
Table 8 South Korea: Time, Cost, and Complexity of Registration Process
5.5 Reimbursement Scenario
Table 9 Reimbursement Codes for Various Biomarkers
5.6 Value Chain Analysis
Figure 20 Cardiac Marker Testing Market: Value Chain Analysis
5.7 Ecosystem: Parent Industry (In Vitro Diagnostics)
5.8 Se Cases: in Vitro Diagnostics Market
5.8.1 Revenue Opportunities: IVD Assay Development Services
5.8.2 Revenue Opportunities: IVD Contract Research Services

6 Cardiac Marker Testing Market, by Product
6.1 Introduction
Table 10 Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
6.2 Reagents & Kits
6.2.1 Increasing Number of Tests Performed to Drive the Market Growth
Table 11 Cardiac Marker Testing Reagents and Kits Market, by Region, 2018-2025 (USD Million)
Table 12 Cardiac Marker Testing Reagents and Kits Market, by Biomarker Type, 2018-2025 (USD Million)
6.3 Instruments
Table 13 Cardiac Marker Testing Instruments Market, by Technique, 2018-2025 (USD Million)
Table 14 Cardiac Marker Testing Instruments Market, by Biomarker Type, 2018-2025 (USD Million)
Table 15 Cardiac Marker Testing Instruments Market, by Region, 2018-2025 (USD Million)
6.3.1 Chemiluminescence
6.3.1.1 Chemiluminescence is the Most Preferred Method for the Quantification of Cardiac Biomarkers
Table 16 Cardiac Marker Testing Instruments Market for Chemiluminescence, by Region, 2018-2025 (USD Million)
Table 17 Cardiac Marker Testing Instruments Market for Chemiluminescence, by Biomarker Type, 2018-2025 (USD Million)
6.3.2 Immunofluorescence
6.3.2.1 Demand for Stable and Safer Reagents to Support Market Growth
Table 18 Cardiac Marker Testing Instruments Market for Immunofluorescence, by Region, 2018-2025 (USD Million)
Table 19 Cardiac Marker Testing Instruments Market for Immunofluorescence, by Biomarker Type, 2018-2025 (USD Million)
6.3.3 ELISA
6.3.3.1 Ease of Use and Simplicity of the Method are the Key Advantages Associated with ELISA
Table 20 Cardiac Marker Testing Instruments Market for ELISA, by Region, 2018-2025 (USD Million)
Table 21 Cardiac Marker Testing Instruments Market for ELISA, by Biomarker Type, 2018-2025 (USD Million)
6.3.4 Immunochromatography
6.3.4.1 Increasing Use in Point-Of-Care Settings to Fuel the Adoption of this Technique
Table 22 Cardiac Marker Testing Instruments Market for Immunochromatography, by Region, 2018-2025 (USD Million)
Table 23 Cardiac Marker Testing Instruments Market for Immunochromatography, by Biomarker Type, 2018-2025 (USD Million)

7 Cardiac Marker Testing Market, by Biomarker Type
7.1 Introduction
Table 24 Cardiac Marker Testing Market, by Biomarker Type, 2018-2025 (USD Million)
7.2 Troponin I and T
7.2.1 High Sensitivity of this Biomarker Test is Supporting Its Increased Adoption in the Market
Table 25 Characteristics of Troponin Cardiac Markers
Table 26 Cardiac Marker Testing Market for Troponin I and T, by Region, 2018-2025 (USD Million)
Table 27 Cardiac Marker Testing Market for Troponin I and T, by Disease, 2018-2025 (USD Million)
Table 28 Cardiac Marker Testing Market for Troponin I and T, by End-user, 2018-2025 (USD Million)
7.3 CK-MB
7.3.1 CK-MB is Useful for the Diagnosis of Acute Myocardial Injury
Table 29 Characteristics of CK-MB Cardiac Markers
Table 30 Cardiac Marker Testing Market for CK-MB, by Region, 2018-2025 (USD Million)
Table 31 Cardiac Marker Testing Market for CK-MB, by Disease, 2018-2025 (USD Million)
Table 32 Cardiac Marker Testing Market for CK-MB, by End-user, 2018-2025 (USD Million)
7.4 BNP and NT-proBNP
7.4.1 The Ability of this Biomarker to be Used with Other Markers is Supporting Market Growth
Table 33 Cardiac Marker Testing Market for BNP and NT-proBNP, by Region, 2018-2025 (USD Million)
Table 34 Cardiac Marker Testing Market for BNP and NT-proBNP, by Disease, 2018-2025 (USD Million)
Table 35 Cardiac Marker Testing Market for BNP and NT-proBNP, by End-user, 2018-2025 (USD Million)
7.5 Myoglobin
7.5.1 Rapid Increase and Normalization Associated with Myoglobin to Drive Market Growth
Table 36 Characteristics of Myoglobin Cardiac Markers
Table 37 Cardiac Marker Testing Market for Myoglobin, by Region, 2018-2025 (USD Million)
Table 38 Cardiac Marker Testing Market for Myoglobin, by Disease, 2018-2025 (USD Million)
Table 39 Cardiac Marker Testing Market for Myoglobin, by End-user, 2018-2025 (USD Million)
7.6 hsCRP
7.6.1 Ability of hsCRP Tests to Accurately Measure Low Levels of CRP Will Support Market Growth
Table 40 Cut-Offs for CRP Using Standardized Assay
Table 41 Cardiac Marker Testing Market for hsCRP, by Region, 2018-2025 (USD Million)
Table 42 Cardiac Marker Testing Market for hsCRP, by Disease, 2018-2025 (USD Million)
Table 43 Cardiac Marker Testing Market for hsCRP, by End-user, 2018-2025 (USD Million)
7.7 Other Biomarkers
Table 44 Cardiac Marker Testing Market for Other Biomarkers, by Region, 2018-2025 (USD Million)
Table 45 Cardiac Marker Testing Market for Other Biomarkers, by Disease, 2018-2025 (USD Million)
Table 46 Cardiac Marker Testing Market for Other Biomarkers, by End-user, 2018-2025 (USD Million)

8 Cardiac Marker Testing Market, by Disease
8.1 Introduction
Table 47 Cardiac Marker Testing Market, by Disease, 2018-2025 (USD Million)
8.2 Myocardial Infarction
8.2.1 Availability of High-Sensitivity Biomarkers for the Detection of Mi to Support Market Growth
Table 48 Cardiac Marker Testing Market for Myocardial Infarction, by Region, 2018-2025 (USD Million)
8.3 Congestive Heart Failure
8.3.1 Growing Use of Multi-Marker Testing is Driving Market Growth
Table 49 Cardiac Marker Testing Market for Congestive Heart Failure, by Region, 2018-2025 (USD Million)
8.4 Acute Coronary Syndrome
8.4.1 Increasing Incidence of Risk Factors Associated with Acs to Drive the Adoption of Cardiac Markers
Table 50 Cardiac Marker Testing Market for Acute Coronary Syndrome, by Region, 2018-2025 (USD Million)
8.5 Atherosclerosis
8.5.1 High Prevalence of Atherosclerosis Will Propel the Adoption of Cardiac Markers
Table 51 Cardiac Marker Testing Market for Atherosclerosis, by Region, 2018-2025 (USD Million)
8.6 Ischemia
8.6.1 Multiple Complications Caused by Ischemia is Resulting in the Increased Adoption of Diagnostics Tests
Table 52 Cardiac Marker Testing Market for Ischemia, by Region, 2018-2025 (USD Million)

9 Cardiac Marker Testing Market, by End-user
9.1 Introduction
Table 53 Cardiac Marker Testing Market, by End-user, 2018-2025 (USD Million)
9.2 Laboratory Testing Facilities
Table 54 Cardiac Marker Testing Market for Laboratory Testing Facilities, by Type, 2018-2025 (USD Million)
Table 55 Cardiac Marker Testing Market for Laboratory Testing Facilities, by Region, 2018-2025 (USD Million)
9.2.1 Hospital Laboratories
9.2.1.1 Emergency Patient Care and Early Diagnosis Associated with In-House Labs to Drive Market Growth
Table 56 Cardiac Marker Testing Market for Hospital Laboratories, by Region, 2018-2025 (USD Million)
9.2.2 Reference Laboratories
9.2.2.1 Cost and Time Savings Associated with Reference Laboratories to Support Market Growth
Table 57 Cardiac Marker Testing Market for Reference Laboratories, by Region, 2018-2025 (USD Million)
9.2.3 Contract Testing Laboratories
9.2.3.1 Access to a Wide Range of Tests in Such Settings Allows Multiple Tests to be Performed
Table 58 Cardiac Marker Testing Market for Contract Testing Laboratories, by Region, 2018-2025 (USD Million)
9.3 Academic Institutes
9.3.1 Continuous Research & Development of Novel Biomarkers to Drive Market Growth
Table 59 Cardiac Marker Testing Market for Academic Institutes, by Region, 2018-2025 (USD Million)
9.4 Point-Of-Care Testing Facilities
9.4.1 Early Detection and Lower Turnaround Test Time Will Drive Market Growth
Table 60 Cardiac Marker Testing Market for POC Testing Facilities, by Region, 2018-2025 (USD Million)

10 Cardiac Marker Testing Market, by Region
10.1 Introduction
Table 61 Cardiac Marker Testing Market, by Region, 2018-2025 (USD Million)
10.2 North America
Figure 21 North America: Cardiac Marker Testing Market Snapshot
Table 62 North America: Cardiac Marker Testing Market, by Country, 2018-2025 (USD Million)
Table 63 North America: Cardiac Marker Testing Market, by Biomarker Type, 2018-2025 (USD Million)
Table 64 North America: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
Table 65 North America: Cardiac Marker Testing Instruments Market, by Technology, 2018-2025 (USD Million)
Table 66 North America: Cardiac Marker Testing Market, by End-user, 2018-2025 (USD Million)
10.2.1 US
10.2.1.1 Increasing Public-Private Investments for Cardiac Biomarker Research to Drive Market Growth
Table 67 US: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.2.2 Canada
10.2.2.1 Increasing Government Initiatives to Support the Cardiac Marker Testing Market in Canada
Table 68 Canada: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.3 Europe
Table 69 Europe: Cardiac Marker Testing Market, by Country, 2018-2025 (USD Million)
Table 70 Europe: Cardiac Marker Testing Market, by Biomarker Type, 2018-2025 (USD Million)
Table 71 Europe: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
Table 72 Europe: Cardiac Marker Testing Instruments Market, by Technology, 2018-2025 (USD Million)
Table 73 Europe: Cardiac Marker Testing Market, by End-user, 2018-2025 (USD Million)
10.3.1 Germany
10.3.1.1 Higher Healthcare Spending to Fuel Diagnostic Testing
Table 74 Germany: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.3.2 UK
10.3.2.1 Increasing Number of Accredited Clinical Laboratories to Increase the Adoption of Cardiac Marker Tests in the Country
Table 75 UK: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.3.3 France
10.3.3.1 Increasing Demand for Early Disease Diagnosis to Drive Market Growth
Table 76 France: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.3.4 Italy
10.3.4.1 Increasing Prevalence of Chronic and Infectious Diseases to Drive Market Growth
Table 77 Italy: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.3.5 Spain
10.3.5.1 Rising Geriatric Population in the Country to Support Market Growth
Table 78 Spain: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.3.6 Rest of Europe (RoE)
Table 79 Rest of Europe: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.4 Asia-Pacific
Figure 22 Asia-Pacific: Cardiac Marker Testing Market Snapshot
Table 80 Asia-Pacific: Cardiac Marker Testing Market, by Country, 2018-2025 (USD Million)
Table 81 Asia-Pacific: Cardiac Marker Testing Market, by Biomarker Type, 2018-2025 (USD Million)
Table 82 Asia-Pacific: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
Table 83 Asia-Pacific: Cardiac Marker Testing Instruments Market, by Technology, 2018-2025 (USD Million)
Table 84 Asia-Pacific: Cardiac Marker Testing Market, by End-user, 2018-2025 (USD Million)
10.4.1 Japan
10.4.1.1 Presence of a Well-Developed Healthcare System to Drive Market Growth in Japan
Table 85 Japan: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.4.2 China
10.4.2.1 Increasing Disposable Income of the Chinese Population to Fuel Market Growth
Table 86 China: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.4.3 India
10.4.3.1 Presence of a Large Patient Population to Fuel the Demand for Cardiac Marker Testing in the Country
Table 87 India: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.4.4 South Korea
10.4.4.1 Growing Number of Private Hospitals and Independent Testing Laboratories to Drive Market Growth
Table 88 South Korea: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.4.5 Australia
10.4.5.1 High Healthcare Expenditure in the Country to Support Market Growth
Table 89 Australia: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.4.6 Rest of Asia-Pacific (RoAPAC)
Table 90 Rest of Asia-Pacific: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.5 Latin America
Table 91 Latin America: Cardiac Marker Testing Market, by Country, 2018-2025 (USD Million)
Table 92 Latin America: Cardiac Marker Testing Market, by Biomarker Type, 2018-2025 (USD Million)
Table 93 Latin America: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
Table 94 Latin America: Cardiac Marker Testing Instruments Market, by Technology, 2018-2025 (USD Million)
Table 95 Latin America: Cardiac Marker Testing Market, by End-user, 2018-2025 (USD Million)
10.5.1 Brazil
10.5.1.1 Rising Investments by Leading IVD Manufacturers in the Country to Drive Market Growth
Table 96 Brazil: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.5.2 Mexico
10.5.2.1 Availability of Technologically Advanced IVD Products in the Country to Propel Market Growth
Table 97 Mexico: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.5.3 Rest of Latin America
Table 98 Rest of Latin America: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
10.6 Middle East & Africa
10.6.1 Improving Healthcare Infrastructure to Drive Market Growth
Table 99 Middle East & Africa: Cardiac Marker Testing Market, by Biomarker Type, 2018-2025 (USD Million)
Table 100 Middle East & Africa: Cardiac Marker Testing Market, by Product, 2018-2025 (USD Million)
Table 101 Middle East & Africa: Cardiac Marker Testing Instruments Market, by Technology, 2018-2025 (USD Million)
Table 102 Middle East & Africa: Cardiac Marker Testing Market, by End-user, 2018-2025 (USD Million)

11 Competitive Landscape
11.1 Introduction
11.2 Strategic Overview
Figure 23 Key Developments in the Cardiac Marker Testing Market, 2017-2020
11.3 Market Share Analysis
Figure 24 Cardiac Marker Testing Market Share, by Key Player, 2019
11.4 Competitive Scenario
11.5 Key Market Developments
11.5.1 Product Launches and Approvals
11.5.2 Acquisitions
11.5.3 Partnerships, Collaborations, and Agreements
11.5.4 Expansions

12 Company Evaluation Matrix and Company Profiles
12.1 Company Evaluation Matrix
12.1.1 Stars
12.1.2 Emerging Leaders
12.1.3 Emerging Companies
12.1.4 Pervasive
Figure 25 Cardiac Marker Testing Market: Competitive Leadership Mapping, 2019
12.2 Company Profiles
(Business Overview, Products Offered, Recent Developments, Analyst's View)*
12.2.1 Abbott Laboratories
Figure 26 Abbott Laboratories: Company Snapshot (2019)
12.2.2 Becton, Dickinson and Company
Figure 27 Becton, Dickinson and Company: Company Snapshot (2019)
12.2.3 bioMérieux SA
Figure 28 bioMérieux SA: Company Snapshot (2019)
12.2.4 Bio-Rad Laboratories, Inc.
Figure 29 Bio-Rad Laboratories: Company Snapshot (2019)
12.2.5 Danaher Corporation
Figure 30 Danaher Corporation: Company Snapshot (2019)
12.2.6 Diasorin
Figure 31 Diasorin: Company Snapshot (2019)
12.2.7 F. Hoffmann-La Roche AG
Figure 32 F. Hoffmann-La Roche AG: Company Snapshot (2019)
12.2.8 Guangzhou Wondfo Biotech Co., Ltd.
12.2.9 LSI Medience Corporation
Figure 33 Mitsubishi Chemical Holdings Corporation: Company Snapshot (2019)
12.2.10 Ortho Clinical Diagnostics
12.2.11 Perkinelmer, Inc.
Figure 34 Perkinelmer: Company Snapshot (2019)
12.2.12 Randox Laboratories
12.2.13 Siemens Healthineers AG
Figure 35 Siemens Healthineers AG: Company Snapshot (2019)
12.2.14 Thermo Fisher Scientific
Figure 36 Thermo Fisher Scientific: Company Snapshot (2019)
12.2.15 Tosoh Corporation
Figure 37 Tosoh Corporation: Company Snapshot (2019)
*Business Overview, Products Offered, Recent Developments, Analyst's View Might Not be Captured in Case of Unlisted Companies

13 Appendix
13.1 Discussion Guide
13.2 Knowledge Store: The Subscription Portal
13.3 Available Customizations

Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Danaher Corporation
  • Diasorin
  • F. Hoffmann-La Roche AG
  • Guangzhou Wondfo Biotech Co. Ltd.
  • LSI Medience Corporation
  • Ortho Clinical Diagnostics
  • Perkinelmer, Inc.
  • Randox Laboratories
  • Siemens Healthineers AG
  • Thermo Fisher Scientific
  • Tosoh Corporation
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll